Autolus Therapeutics plc reported second quarter 2026 financial results, announcing net product revenue of $45.7 million for the three months ended June 30, 2026, a 119% increase year-over-year. The company raised its full-year 2026 net product revenue guidance to $140–$150 million from $120–$135 million and reported a gross margin of 55%, up from negative margins in prior periods. Autolus secured a five-year, interest-only credit facility with Perceptive Advisors for up to $250 million, with an initial $75 million funded at closing on July 30, 2026. The company also completed a workforce reduction affecting approximately 13% of employees to reduce operating expenses by roughly $15 million annually starting in 2027. Autolus Therapeutics plc is a commercial-stage biopharmaceutical company developing and delivering next-generation T cell therapies for cancer and autoimmune diseases.

Autolus Therapeutics plc updated its full-year 2026 net product revenue guidance for AUCATZYL (obe-cel) to $140 million–$150 million, up from $120 million–$135 million. The company reported preliminary Q2 2026 net product revenue of approximately $45 million with a gross margin of roughly 35%. Autolus also secured a strategic five-year, interest-only credit facility with Perceptive Advisors for up to $250 million in aggregate principal amount. An initial $75 million was issued on July 30, 2026, with an additional $25 million available at the company's option and further tranches contingent on revenue milestones. The financing includes a warrant to purchase up to 3.5 million ADSs at $1.9314 per share. Combined with existing cash reserves, the capital base supports operations into the second quarter of 2028. Autolus Therapeutics plc is a commercial-stage biopharmaceutical company developing and delivering next-generation T cell therapies for cancer and autoimmune diseases.

Autolus Therapeutics plc entered into a Note Purchase Agreement with Perceptive Credit Holdings V, LP on July 30, 2026, establishing a senior secured notes facility with an aggregate principal amount of up to $250.0 million. The company issued the first tranche of notes totaling $75.0 million, with additional tranches available subject to revenue milestones and timing constraints through January 2030. The facility matures on July 30, 2031, accrues interest based on SOFR plus a margin between 6.75% and 7.25%, and requires the maintenance of minimum liquidity and consolidated net revenue covenants. Concurrently, Autolus issued warrants to purchase up to 3,500,000 American Depositary Shares at an exercise price of $1.9314 per share, with additional warrants issuable upon future tranches. The company operates in the biotechnology industry, specializing in the development of CAR T-cell therapies for cancer treatment.

Autolus Therapeutics plc published its UK Annual Report and Accounts for the year ended December 31, 2025, and distributed notice for its annual general meeting to be held on June 29, 2026. The company is a biotechnology company that develops CAR-T cell therapies for cancer.